| Wissenschaftl. Titel | A phase III, multicenter, randomized, open label study of atezolizumab (anti pd-l1 antibody) plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation |
| Erkrankung |
Gastro:
Leber/Galle:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 30.11.2020 Data entry XI CCP
geändert 30.11.2020 Data entry XI CCP